LONDON - Kudos Pharmaceuticals Ltd. raised £29.5 million (US$45.9 million) in third-round funding with plans to take its two lead cancer treatments through Phase II and push further compounds into Phase I. (Bioworld International
LONDON - Kudos Pharmaceuticals Ltd. raised £29.5 million (US$45.9 million) in third-round funding with plans to take its two lead cancer treatments through Phase II and push further compounds into Phase I. (Bioworld International
LONDON - Microscience Ltd. is forming a 50-50 joint venture company with the Hamburg, Germany, drug discovery services company Evotec OAI to develop small-molecule antimicrobial drugs based on targets generated by Microscience's functional genomics platform. (Bioworld International)
